Ouch, That Stung
Yet another reason why I've decided to stay away from rating small cap pharma/biotech/biopharma. A company I put the red thumb down on just got bought out. At a big premium to the current price. For a total score of minus 140 points. I decided to stop prolonging the agony and ended the pick. It dropped me a bunch of places and it will take my score weeks to recover.
The company was Bioveris (BIOV) and it put a severe hurt on my score.
I'm glad I did this in CAPS and not with real money, that could have been a seriously bad scene.